Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Purple Biotech Ltd - ADR (OQ:PPBT)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for PPBT*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 28, 2024 07:00 ET
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance,...
Read full article
Mar 14, 2024 07:30 ET
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance,...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.94
--
--
Price to Sales - TTM
--
6.15
3.35
Price to Book - most recent quarter
0.49
2.46
2.24
Price to Cash Flow per share - TTM
--
17.95
14.64
Price to Free Cash Flow per share - TTM
--
17.54
24.97
See all valuations

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

See business summary

 

Twitter

Search (past week) for $PPBT

  • No tweets found